SCHEMBL6324772

SCHEMBL6324772

Cc1cc(C(=O)O)c(/C=C2\C(=O)Nc3cccc(-c4cccc(CCO)c4)c32)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 5/20 0.47
ALK Q9UM73 8/20 0.46
KDR P35968 9/20 0.43
FGFR1 P11362 6/20 0.43
RET P07949 5/20 0.43
FLT3 P36888 4/20 0.43
PDGFRB P09619 4/20 0.43
CSF1R P07333 3/20 0.43
FGFR3 P22607 3/20 0.43
FLT4 P35916 3/20 0.43
AURKA O14965 3/20 0.43
MAP4K2 Q12851 3/20 0.43
STK3 Q13188 3/20 0.43
AURKB Q96GD4 3/20 0.43
SRC P12931 2/20 0.43
MAPK1 P28482 2/20 0.43
ZAP70 P43403 2/20 0.43
PLK4 O00444 2/20 0.43
PDPK1 O15530 2/20 0.43
JAK2 O60674 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321139 0.90 ALK (0.53) FLT1ALKKDRFGFR1RET
SCHEMBL6327946 0.86 ALK (0.51) FLT1ALKKDRFGFR1RET
SCHEMBL6319389 0.85 ALK (0.48) FLT1ALKKDRFGFR1RET
SCHEMBL6319360 0.85 ALK (0.48) FLT1ALKKDRFGFR1RET
SCHEMBL6320935 0.85 ALK (0.48) FLT1ALKKDRFGFR1RET
SCHEMBL6324427 0.85 ALK (0.48) FLT1ALKKDRFGFR1RET
SCHEMBL6319385 0.85 ALK (0.48) FLT1ALKKDRFGFR1RET
SCHEMBL6320158 0.85 ALK (0.52) FLT1ALKKDRFGFR1RET
SCHEMBL6321260 0.85 ALK (0.39) FLT1ALKKDRFGFR1RET
SCHEMBL6321181 0.84 ALK (0.48) FLT1ALKKDRFGFR1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 FLT1 1811/4885ALK 1015/4885KDR 819/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 FLT1 1811/4885ALK 1015/4885KDR 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.